Literature DB >> 14998079

In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates.

A J Carrillo-Muñoz1, B Fernandez-Torres, J Guarro.   

Abstract

Three hundred and nine strains belonging to 11 species of dermatophyte moulds were tested against sertaconazole following mainly the National Committee for Clinical Laboratory Standards (M38-P) for filamentous fungi. However, several important factors such as the temperature (28 degrees C vs 35 degrees C) and time of incubation (4-10 d vs 21-74 h), have been modified. Sertaconazole was active against all the clinically important dermatophyte moulds involved in human infections tested. Overall geometric mean MIC of sertaconazole was 0.21 microg/ml with a MIC range of 0.01-8 microg/ml. MIC50 and MIC90 were respectively of 0.25 and 1 microg/ml. Sertaconazole was very active against Epidermophyton floccosum, Trichophyton rubrum, Trichophyton tonsurans and Microsporum canis (geometric means 0.08, 0.13, 0.13 and 0.19 microg/ml respectively). Microsporum audouinii had the lowest susceptibility in the study (geometric mean 0.59 microg/ml). Considering MIC50 and MIC90 these differences were significantly in favor of the activity of sertaconazole against E. floccosum (0.06 and 0.5 microg/ml respectively).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14998079     DOI: 10.1179/joc.2003.15.6.555

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Sertaconazole nitrate shows fungicidal and fungistatic activities against Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, causative agents of tinea pedis.

Authors:  Alfonso J Carrillo-Muñoz; Cristina Tur-Tur; Delia C Cárdenes; Dolors Estivill; Gustavo Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

Review 2.  Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.

Authors:  Jamie D Croxtall; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.